Cost-effectiveness of HER-2 testing strategies to select women with metastatic breast cancer (MBC) for treatment with trastuzumab.

被引：0
|
作者：
Oster, G
Delea, TE
Berger, A
Klein, P
Lieberman, G
Paton, VE
Chawla, A
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] Genentech Inc, San Francisco, CA 94080 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
768
引用
收藏
页码：68S / 68S
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer (MBC) patients in Sweden
    Lidgren, M.
    Rehnberg, C.
    Wilking, N.
    Jonsson, B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer
    Lidgren, Mathias
    Wilking, Nils
    Jonsson, Bengt
    Rehnberg, Clas
    [J]. ACTA ONCOLOGICA, 2008, 47 (06) : 1018 - 1028
  • [3] HER-2 testing and trastuzurnab therapy for metastatic breast cancer: A cost-effectiveness analysis
    Elkin, EB
    Weinstein, KC
    Winer, EP
    Kuntz, KM
    Schnitt, SJ
    Weeks, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) : 854 - 863
  • [4] Trastuzumab (T) and CNS metastases in women with HER-2 positive metastatic breast cancer (MBC).
    Dawson, SJJ
    Ranieri, NF
    Snyder, RD
    McLachlan, SAA
    Burns, WI
    Newnham, GM
    Francis, PA
    Dowling, AJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 49S - 49S
  • [5] A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan
    Diaby, Vakaramoko
    Alqhtani, Hussain
    Van Boemmel-Wegmann, Sascha
    Wang, Ching-Yu
    Ali, Askal Ayalew
    Balkrishnan, Rajesh
    Ko, Yu
    Palacio, Sofia
    Lopes, Gilberto de Lima
    [J]. BREAST, 2020, 49 : 141 - 148
  • [6] A COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB-CONTAINING TREATMENT SEQUENCES FOR HER-2 POSITIVE METASTATIC BREAST CANCER PATIENTS IN TAIWAN
    Diaby, V
    Alqhtani, H.
    van Boemmel-Wegmann, S.
    Wang, C. Y.
    Ali, A. A.
    Balkrishnan, R.
    Ko, Y.
    Palacio, S.
    Lopes, G.
    [J]. VALUE IN HEALTH, 2020, 23 : S40 - S40
  • [7] Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer
    Leung, Henry W. C.
    Chan, Agnes L. F.
    Muo, Chih-Hsin
    Leung, John Hang
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (02) : 207 - 213
  • [8] Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer
    Dickerson, James
    Moen, Marcus
    Nielsen, Perry
    Tran, Edward
    Suen, Wesley
    Goldhaber-Fiebert, Jeremy D.
    Alarid-Escudero, Fernando
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis
    Norum, J
    Risberg, T
    Olsen, JA
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (06) : 909 - 914
  • [10] A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis - Reply
    Bonneterre, ME
    Bonneterre, J
    [J]. ANNALS OF ONCOLOGY, 2006, 17 (05)
12345